Pepro Tech
Originally published online as doi:10.1189/jlb.0708445 on November 12, 2008

Published online before print November 12, 2008
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Supplemental Table 1
Right arrow All Versions of this Article:
jlb.0708445v1
85/2/235    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanaro, C.
Right arrow Articles by Costa, F. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanaro, C.
Right arrow Articles by Costa, F. F.
(Journal of Leukocyte Biology. 2009;85:235-242.)
© 2009 Society for Leukocyte Biology

Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy

C. Lanaro, C. F. Franco-Penteado, D. M. Albuqueque, S. T. O. Saad, N. Conran and F. F. Costa1

Hematology and Hemotherapy Center, School of Medicine, UNICAMP, Campinas, Brazil

1 Correspondence: Centro de Hematologia e Hemoterapia, Faculdade de Ciências Medicas, Rua Carlos Chagas, 480, Cidade Universitária, Barão Geraldo, Campinas 13083-970-SP, Brazil. E-mail: ferreira{at}unicamp.br

ABSTRACT

Inflammation, cell adhesion to vascular endothelium, and endothelial injury contribute to sickle cell anemia (SCA) vaso-occlusion. Although alterations in inflammatory cytokines and biomarkers have been related, reports have been conflicting, and a conclusive role for these molecules in the disease remains to be established. Furthermore, the effect of hydroxyurea therapy (HU) on the release of inflammatory mediators is not understood. This study aimed to determine plasma levels and leukocyte gene expressions of inflammatory mediators in healthy controls, steady-state SCA patients, and SCA patients on HU therapy. TNF-{alpha}, IL-8, and PGE2 levels were significantly higher in the plasma of SCA individuals when compared with control individuals. HU therapy was associated with a significant reversal of augmented TNF-{alpha} and, interestingly, increased plasma anti-inflammatory IL-10. IFN-{gamma}, IL-10, cyclooxygenase 2 (COX-2), and inducible NO synthase (iNOS) gene expressions were unaltered in SCA mononuclear cells (MC); however, gene expressions of TNF-{alpha}, IL-8, and the protective enzyme heme oxygenase-1 (HO-1) were significantly higher. HU therapy was not associated with significantly altered SCA MC inflammatory gene expression, although COX-2 mRNA expression was decreased. In SCA neutrophils, gene expressions of IL-8, IFN-{gamma}, iNOS, and HO-1 were significantly higher than those of control subjects. Patients on HU demonstrated lower iNOS and higher IL-10 neutrophil gene expressions. Taken together, data suggest that alterations in the gene expressions and productions of a number of pro- and anti-inflammatory mediators are present in SCA and importantly, in those patients on HU therapy. Knowledge of these pathways may contribute to further the understanding of the pathophysiology of this disease.

Key Words: neutrophil • mononuclear cell • chemokines • heme oxygenase • gene expression